WO2001066087A1 - New self emulsifying drug delivery system - Google Patents

New self emulsifying drug delivery system Download PDF

Info

Publication number
WO2001066087A1
WO2001066087A1 PCT/SE2001/000466 SE0100466W WO0166087A1 WO 2001066087 A1 WO2001066087 A1 WO 2001066087A1 SE 0100466 W SE0100466 W SE 0100466W WO 0166087 A1 WO0166087 A1 WO 0166087A1
Authority
WO
WIPO (PCT)
Prior art keywords
oil
pharmaceutical composition
surfactant
pharmaceutical
composition according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/SE2001/000466
Other languages
English (en)
French (fr)
Inventor
Christina Holmberg
Britta Siekmann
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
AstraZeneca AB
Original Assignee
AstraZeneca AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to CA002401857A priority Critical patent/CA2401857A1/en
Priority to KR1020027011733A priority patent/KR100771318B1/ko
Priority to US10/221,079 priority patent/US7736666B2/en
Priority to SK1258-2002A priority patent/SK285749B6/sk
Priority to DE60115402T priority patent/DE60115402T2/de
Priority to AU2001237875A priority patent/AU2001237875B2/en
Priority to HU0300539A priority patent/HU229103B1/hu
Priority to EP01910304A priority patent/EP1267831B1/en
Priority to PL358617A priority patent/PL203549B1/pl
Application filed by AstraZeneca AB filed Critical AstraZeneca AB
Priority to BRPI0109012-7A priority patent/BR0109012B1/pt
Priority to AU3787501A priority patent/AU3787501A/xx
Priority to IL15138001A priority patent/IL151380A0/xx
Priority to HK03106084.1A priority patent/HK1053795B/xx
Priority to SI200130487T priority patent/SI1267831T1/sl
Priority to AT01910304T priority patent/ATE311173T1/de
Priority to EEP200200483A priority patent/EE200200483A/xx
Priority to JP2001564740A priority patent/JP4656479B2/ja
Priority to MXPA02008658A priority patent/MXPA02008658A/es
Priority to UA2002086882A priority patent/UA76098C2/uk
Publication of WO2001066087A1 publication Critical patent/WO2001066087A1/en
Priority to NO20024194A priority patent/NO331921B1/no
Priority to IS6538A priority patent/IS6538A/is
Anticipated expiration legal-status Critical
Priority to US12/768,820 priority patent/US20100266683A1/en
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect

Definitions

  • the present invention is directed to a new pharmaceutical composition in form of an emulsion pre-concentrate. a unit dosage form comprising said composition, its use in therapy as well as a process for the preparation thereof.
  • Non-steroidal anti-inflammatory drugs are well-known drugs for the treatment of pain and inflammation.
  • One of the major drawbacks with NSAIDs is that they have severe gastro-intestinal side-effects. Patients undergoing treatment with NSAIDs for a longer period of time, such as naproxen, often experience problems with stomach gastrointestinal side-effects.
  • Nitrogen oxide releasing NSAID compounds in the following NO-releasing NSAIDs, have recently been found to have an improved side-effect profile, see e.g. WO 94/04484, WO 94/12463, WO 95/09831 and WO 95/30641.
  • NO-releasing NSAIDs are lipophilic compounds with poor aqueous solubility. They can be classified into class 2 according to the Biopharmaceutical Classification System proposed by Amidon et al. (Pharm. Res. 12 (1995) pp. 413-420). Drugs of this class are characterised by low aqueous solubility but reasonably well permeability. A biopharmaceutical problem with these compounds is that their absorption from the gastrointestinal tract (GIT) may be dissolution rate limited, resulting in poor bioavailibility upon oral administration.
  • GIT gastrointestinal tract
  • WO 95/08983 discloses a self-emulsifying composition for oral administration that forms a microemulsion in situ when in contact with biological fluids
  • This composition can be characterised as a self-microemulsifying drug delivery system (SMEDDS), and comprises at least - an active compound.
  • SMEDDS self-microemulsifying drug delivery system
  • a lipophilic phase consisting of a mixture ot glyce ⁇ des and fatty acid esters.
  • a surface-active agent consisting of a mixture ot glyce ⁇ des and fatty acid esters.
  • a surface-active agent consisting of a mixture ot glyce ⁇ des and fatty acid esters.
  • a surface-active agent consisting of a mixture ot glyce ⁇ des and fatty acid esters.
  • a surface-active agent consisting of a mixture ot glyce ⁇ des and fatty acid esters
  • a surface-active agent consisting of a mixture o
  • compositions of WO 95/08983 comprise inter alia a cosurfactant in addition to a surface-active agent. The presence of a cosurfactant is not necessary for compositions of the present invention reducing toxicological concern to a minimum
  • EP 274 870 discloses a pharmaceutical composition
  • a pharmaceutical composition comprising a non-steroidal anti- lnflammatory drug (NSAID) and a surfactant, the composition being capable of forming micelles containing the NSAID upon oral administration.
  • NSAID non-steroidal anti- lnflammatory drug
  • GIT gastrointestinal tract
  • Micelles are aggregates in which the surfactant molecules are generally arranged in a spheroidal structure with the hydrophobic region at the core shielded, in an aqueous solution, from the water by a mantle of outer hydrophilic regions.
  • the drug is usually solubihsed in the surfactant.
  • Micelles are to be contrasted in terms of their structure with emulsions which are formed by compositions of the present invention. Whereas micelles are thermodynamically stable one-phase-systems (according to the Gibbs phase law) in which the aggregates usually have a diameter of approximately two lengths of the surfactant molecule forming it, i.e.
  • emulsions are much larger aggregates the order ot nanometers to micrometers in diameter, consisting ot an oilv core which is surrounded by one or several layers of surfactants Emulsions are generally two-phase-systems and they are thermodynamicallv unstable (but may be ineticallv stable)
  • Another major difference between the compositions ot EP 274 870 and the present invention is the nature of the active compound Whereas NSAIDs are crystalline powders by nature, the NO-releasmg NSAIDs or mixtures of NO-releasing NSAIDs used in the present invention are in oil form or a thermosoftemng semisolid Moreover, micelles usually iequire a much higher drug surfactant ratio compared to the oil surfactant ratio required to form an emulsion
  • NO-releasing NSAIDs are oils or thermosofte ng semisohds which are practically insoluble in water
  • high- dose NO-releasing NSAIDs e g when the dose is above about 350 mg, it is difficult to formulate a tablet of reasonable size of the large amount of oil or semisolid
  • the lipophilic NO-releasing NSAIDs can, however, be formulated as oil-in-water emulsions where the compound constitutes, or is part of, the oil phase emulsified in water by one or more surfactants
  • the problems mentioned above have now been solved by providing a novel Self Emulsifying Drug Delivery System, commonly known as SEDDS, suitable for oral administration More particularly, the present invention is directed to a pharmaceutical composition suitable tor oral administration, in form of an emulsion pre-concentrate comprising
  • composition forming an in-situ oil-in-water emulsion upon contact with aqueous media such as gastrointestinal fluids
  • composition according to the present invention may optionally further comprise one or more short-chain alcohols
  • the composition will form an in situ oil-in-water emulsion of small droplets of nanometer to micron size upon contact with gastrointestinal fluids, the droplets being constituted of a compound of the formula (I) above, forming the core of the droplet which is covered by one or several layers of surfactant
  • the in situ formed oil-in-water emulsion will provide a good bioavailability of the compound of the formula (I) upon oral administration
  • Storage stability of the emulsion is not a concern since the emulsion is not formed until the pre- concentrate has been taken by the patient, 1 e first at the moment of administration
  • the possibly unpleasant taste of the pre-concentrate is not a problem when filled into capsules
  • the pharmaceutical composition according to the present invention is an emulsion pre-concentrate at the time of administration to a patient
  • the emulsion pre-concentrate can be filled into single unit dosage forms such as capsules, drinking ampoules and dose cushions, or may alternatively be formed as other suitable dosage forms such as chewable soft pills
  • the emulsion pre- concentrate Upon contact with aqueous media such as gastrointestinal fluids, the emulsion pre- concentrate transforms into an oil-in-water emulsion
  • the composition will form an in-situ oil-in-water emulsion in the gastrointestinal tract (GI tract)
  • the drug release rate of the composition is determined by the droplet size of the in situ emulsion and the polarity ot the emulsion droplets, the latter being governed by the hydrophihc-lipophilic balance (HLB) of the drug/surfactant mixture, and the concentration of the surfactant
  • HLB hydrophihc-lipophilic balance
  • small droplet size and high polarity gives rise to a high drug release rate (N H Shah et al Int J Pharm 106 (1994) pp 15-23)
  • the compound of the formula (I) above consists of naproxen, a butyl spacer and a NO-releasing moiety, said three parts being linked together into one single molecule Naproxen is by nature in form of a powder, whereas NO-releasing naproxen of the formula (I) above provides a compound in oil form as such at room temperature, due to the spacer
  • NO-releasing naproxen of the formula (I) above provides a compound in oil form as such at room temperature, due to the spacer
  • a pharmacologically inert oil or semisolid fat may be added to the pharmaceutical composition by means of a filler or as a viscosity regulator
  • a filling agent may be required to increase dosing accuracy for low doses
  • a viscosity regulator may be required in order to adjust optimal viscosity for filling of the composition into e g capsules In particular high speed liquid filling of capsules requires careful adjustment of viscosity within a range that prevents splashing on the low viscosity end and thread
  • the total amount of the compound of the formula (I) used in the composition of the s invention is preferably in the range 50- 1500 mg per unit dose In still a further preferred embodiment, the amount of the compound of the formula (I) used in the composition is
  • unit dose is defined as the amount ot active compound administered in one lo single capsule, or dissolved in one glass of water
  • surfactant is defined as surface-active amphiphihc compounds such as block co-polymers
  • Preferred surfactants in accordance with the present invention are non-ionic surfactants, for example those containing polyethylene glycol (PEG) chains, la particularly block co-polymers such as poloxamers
  • poloxamers examples include Poloxamer 407 (Pluronic F127 "), Poloxamer 401
  • Poloxamer 331 (Pluronic L101 ), Poloxamer 231 (Pluronic L81 ), tetrafunctional 0 polyoxyethylene polyoxypropylene block copolymer of ethylene diamine, known as
  • Poloxamine 908 (Tetronic 908 ), Poloxamine 1307 (Tetronic 1307 " ), Poloxamine 1 107
  • the total amount ot surtactant(s) in accordance with the invention may be within the range of from 12 5-6000 mg preferably of from 100-500 mg
  • the ratio NO-releasing NSAID surfactant may vary from 1 0 1 to 1 10, preferably from 1 0 3 to 1 3
  • ® ATO5 Gelucire is a mixture obtained by mixing mono-, di-, and t ⁇ -esters of glycerol, mono- and di-esters of PEG, or free PEG
  • the pharmaceutical composition of the invention is filled into single dosage torms suitable for oral administration such as capsules, drinking ampoules and dose cushions or may be formulated as other suitable oral dosage forms such as chewable soft pills and chewy-base lozenges
  • the pharmaceutical composition is filled into hard gelatin capsules but capsules from alternative materials such as methylcellulose- based shells, and soft gelatine capsules may also be used
  • the pharmaceutical composition may be dissolved in e g a glass of water, thus allowing the pre-concentrate to form an emulsion which may be taken as an oral solution
  • the compositions intended for dissolution prior to administration may be filled e g into sott gelatine capsules, plastic or aluminium cushions, or plastic or glass ampoules This feature is particularly advantageous for high dose compositions which would require a large capsule, for patients who have difficulty in swallowing capsules, and for pediat ⁇ c patients
  • the pharmaceutical composition of the present invention is filled into capsules
  • Preferred capsules are gelatin capsules which may be soft or hard
  • the hard gelatine capsule consists of two pieces, a cap and a body, one fitting inside the other
  • the hard gelatine capsules are produced empty and filled in a separate operation step
  • the soft gelatin capsule is a capsule which is manufactured and filled in one single operation
  • the emulsion pre-concentrate transforms into an oil-in-water emulsion upon contact with the gastrointestinal fluids, whereby the active drug is released
  • the composition will form an in situ oil-in-water emulsion in the gastrointestinal tract (GI tract)
  • the pharmaceutical composition of the present invention is particularly useful in the treatment of pain and inflammation
  • pain is intended to include, but not limited to, nociceptive and neuropathic pain or combinations thereof acute, intermittent and chronic pain, cancer pain, migraine and headaches of similar origin
  • inflammation ' is intended to include, but not limited to, rheumatoid arthritis ostheoarth ⁇ tis. and juvenile arthritis
  • the pharmaceutical composition of the present invention may be prepared mainly by the following alternative methods
  • the oily compound of the formula (I) is put in a vessel and fluid surfactant is added The mixture is mixed thoroughly until homogenous (visual inspection) and the pre-concentrate is filled into capsules suitable for oral administration
  • the oily compound of the formula (I) is put in a vessel, finely grinded (particle size ⁇ 177 um) solid surfactant is added The liquid mixture is mixed thoroughly until homogenous (visual inspection) and the pre-concentrate is filled into capsules suitable for oral administration
  • the semi-solid/sohd surfactant (s) is put in a vessel, and one or more alcohols are added The mixture is heated to the temperature corresponding to the melting point of the excipients, making the formulation fluid, mixed thoroughly until homogenous (visual inspection) The oily compound of the formula (I) is added, and the mixture is mixed thoroughly until homogenous (visual inspection). The pre-concentrate is filled into capsules suitable for oral administration.
  • the formulation In order to fill a two-piece capsule or a softgel capsule with a liquid, the formulation must be within a certain viscosity range, as determined by the manufacturer, at the filling temperature suitable for the process. For a two-piece capsule the maximum filling temperature is roughly 70 °C.
  • process temperature is not allowed to exceed 30-40 °C (the exact temperature depending on the manufacturer).
  • the formulation must be liquid and have a viscosity that allows it to be pumpable at the filling temperature. In order to make the formulation liquid with an acceptable viscosity, several
  • ® additives may be used, for example Cremophor EL .
  • the composition is in liquid form at the temperature of filling.
  • Semisolid thermosoftening compositions are therefore filled above the liqueifying temperature.
  • Soft gelatine capsules are manufactured and filled in one operation, and may be filled at temperatures of up to 40 °C, whereas hard gelatine capsules may be filled at temperatures of up to 70 °C.
  • Hard gelatin capsules filled with compositions that remain liquid at storage temperature require sealing, e.g. by gelatin banding, to prevent leakage.
  • the process of liquid filling of hard gelatin capsules and product requirements are e.g. described in W.J. Bowtle, Pharmaceutical Technology Europe, October 1998; V.M.
  • capsules permit filling of more than one phase into a single capsule which may be desired for bi-or multiphase drug release (W J Bow tie et al Int J Pharm 141 (1996) pp 9-16)
  • phases ot solidifying material can be filled in single steps
  • the final phase may be liquid if required
  • the number of phases is only restricted by the capsule size, and volume ot the single phases
  • This special feature may also allow controlled release or separation of different drug substances formulated in the same capsule
  • capsules may be processed further e g by enteric coating
  • the time for emulsion formation will vary from 30 seconds and up to 15 minutes, depending on the composition of the formulation If one or more short-chain alcohols are added, the time for emulsion formation will vary between 2-3 seconds and 3-4 minutes Also the average particle size of the formed emulsion is studied with Laser Diffraction, LD, or Photon Correlation Spectroscopy, PCS Depending on particle size either of the two methods may be used Detailed description of the invention
  • a liquid formulation was prepared by mixing 1 kg of the liquid surfactant Poloxamer 401, with 1 kg of the compound of formula (I) at room temperature The liquid formulation was mixed until homogenous (checked by visual inspection) The resulting liquid formulation was then filled into hard gelatin capsules
  • the active compound may be filled up to volume with aliquot part coconut oil.
  • a semi-solid formulation was obtained by melting 1.500 kg of Pluronic F 127 ® (Poloxamer 407) by heating to 62 C. The melt was stirred thoroughly to ensure that no solid particles were present. 1.250 kg of the compound of formula (I) and 1.880 kg of fractionated coconut oil were added to the melted
  • a liquid formulation was prepared A solution of 0 506 gram of Pluronic L101 (Poloxamer 331), 0 169 gram of sorbitanmonolaurat and 0 225 gram of ethanol, was mixed until homogenous (checked by visual inspection) 3 Grams of the compound of formula (I) was added to the mixture, at room temperature The resulting liquid formulation was then filled into soft gelatin capsules
  • a pharmaceutical composition of the invention filled in a suitable unit dosage form according to the invention, was administered to each animal
  • the dose levels were approximately 15 ⁇ mol/kg body weight 10 ml of tap water was given to facilitate the swallowing of the capsule or corresponding unit dosage
  • Blood samples (5 ml) were taken from the jugular vein into Vacutainer tubes containing hepa ⁇ n Blood samples were taken before treatment (0) and at 15, 30 and 45 minutes. 1, 1 5, 2, 4, 7 and 24 hours after treatment

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Rheumatology (AREA)
  • Emergency Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Dispersion Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
PCT/SE2001/000466 2000-03-08 2001-03-06 New self emulsifying drug delivery system Ceased WO2001066087A1 (en)

Priority Applications (22)

Application Number Priority Date Filing Date Title
IL15138001A IL151380A0 (en) 2000-03-08 2001-03-06 New self emulsifying drug delivery system
US10/221,079 US7736666B2 (en) 2000-03-08 2001-03-06 Self emulsifying drug delivery system
SK1258-2002A SK285749B6 (sk) 2000-03-08 2001-03-06 Farmaceutická kompozícia vo forme emulzného predkoncentrátu, jednotková dávková forma s jej obsahoma jej použitie
DE60115402T DE60115402T2 (de) 2000-03-08 2001-03-06 Neues selbstemulgierendes arzneistoffverabreichungssystem
AU2001237875A AU2001237875B2 (en) 2000-03-08 2001-03-06 New self emulsifying drug delivery system
HU0300539A HU229103B1 (en) 2000-03-08 2001-03-06 Self emulsifying drug delivery system
EP01910304A EP1267831B1 (en) 2000-03-08 2001-03-06 New self emulsifying drug delivery system
PL358617A PL203549B1 (pl) 2000-03-08 2001-03-06 Kompozycja farmaceutyczna w postaci prekoncentratu emulsji, jednostkowa posta c dawkowana i zastosowanie kompozycji farmaceutycznej
KR1020027011733A KR100771318B1 (ko) 2000-03-08 2001-03-06 신규한 자가-에멀젼화 약물 전달 시스템
BRPI0109012-7A BR0109012B1 (pt) 2000-03-08 2001-03-06 Composição farmacêutica adequada para administração oral na forma de um pré-concentrado de emulsão, e, forma de dosagem unitária
AU3787501A AU3787501A (en) 2000-03-08 2001-03-06 New self emulsifying drug delivery system
CA002401857A CA2401857A1 (en) 2000-03-08 2001-03-06 New self emulsifying drug delivery system
HK03106084.1A HK1053795B (en) 2000-03-08 2001-03-06 New self emulsifying drug delivery system
MXPA02008658A MXPA02008658A (es) 2000-03-08 2001-03-06 Nuevo sistema para el suministro de farmaco auto-emulsificado.
AT01910304T ATE311173T1 (de) 2000-03-08 2001-03-06 Neues selbstemulgierendes arzneistoffverabreichungssystem
EEP200200483A EE200200483A (et) 2000-03-08 2001-03-06 Uus iseemulgeeruv ravimi manustamise süsteem
JP2001564740A JP4656479B2 (ja) 2000-03-08 2001-03-06 新規な自己乳化薬物送達系
SI200130487T SI1267831T1 (sl) 2000-03-08 2001-03-06 Nov samoemulgirni sistem dajanja zdravil
UA2002086882A UA76098C2 (en) 2000-03-08 2001-06-03 System for drug delivery with capability for self-emulsification and method for treating pain and inflammation
NO20024194A NO331921B1 (no) 2000-03-08 2002-09-03 Nytt selvemulgerende legemiddelavleveringssystem
IS6538A IS6538A (is) 2000-03-08 2002-09-03 Nýtt sjálfgert dropakerfi fyrir lyfjagjöf
US12/768,820 US20100266683A1 (en) 2000-03-08 2010-04-28 New self emulsifying drug delivery system

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE0000774-0 2000-03-08
SE0000774A SE0000774D0 (sv) 2000-03-08 2000-03-08 New formulation

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US12/768,820 Continuation US20100266683A1 (en) 2000-03-08 2010-04-28 New self emulsifying drug delivery system

Publications (1)

Publication Number Publication Date
WO2001066087A1 true WO2001066087A1 (en) 2001-09-13

Family

ID=20278740

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/SE2001/000466 Ceased WO2001066087A1 (en) 2000-03-08 2001-03-06 New self emulsifying drug delivery system

Country Status (28)

Country Link
US (2) US7736666B2 (https=)
EP (1) EP1267831B1 (https=)
JP (1) JP4656479B2 (https=)
KR (1) KR100771318B1 (https=)
CN (1) CN1283229C (https=)
AR (1) AR027554A1 (https=)
AT (1) ATE311173T1 (https=)
AU (2) AU2001237875B2 (https=)
BR (1) BR0109012B1 (https=)
CA (1) CA2401857A1 (https=)
CZ (1) CZ303524B6 (https=)
DE (1) DE60115402T2 (https=)
DK (1) DK1267831T3 (https=)
EE (1) EE200200483A (https=)
ES (1) ES2253354T3 (https=)
HU (1) HU229103B1 (https=)
IL (1) IL151380A0 (https=)
IS (1) IS6538A (https=)
MX (1) MXPA02008658A (https=)
MY (1) MY137749A (https=)
NO (1) NO331921B1 (https=)
RU (1) RU2275908C2 (https=)
SE (1) SE0000774D0 (https=)
SI (1) SI1267831T1 (https=)
SK (1) SK285749B6 (https=)
UA (1) UA76098C2 (https=)
WO (1) WO2001066087A1 (https=)
ZA (1) ZA200207109B (https=)

Cited By (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6613354B2 (en) 1996-01-08 2003-09-02 Astrazeneca Ab Oral pharmaceutical dosage forms comprising a proton pump inhibitor and a NSAID
WO2004000273A1 (en) * 2002-06-25 2003-12-31 Nicox S.A. Oral pharmaceutical forms of liquid drugs having improved bioavailability
WO2004076561A1 (en) * 2003-02-27 2004-09-10 Novasel Australia Pty Ltd Poloxamer emulsion preparations
WO2007012539A3 (en) * 2005-07-26 2007-04-19 Nicox Sa Pharmaceutical formulation of nitrooxyderivatives of nsaids
US7465803B2 (en) 2000-10-12 2008-12-16 Nicox S.A. Nitroderivatives as drugs for diseases having an inflammatory basis
US8802116B2 (en) 2003-02-27 2014-08-12 Novasel Australia Pty. Ltd. Poloxamer emulsion preparations
US9788564B2 (en) 2008-03-20 2017-10-17 Virun, Inc. Compositions containing non-polar compounds
US10220007B2 (en) 2008-03-20 2019-03-05 Virun, Inc. Compositions containing non-polar compounds
US10335385B2 (en) 2010-06-21 2019-07-02 Virun, Inc. Composition containing non-polar compounds
US20230277464A1 (en) * 2022-03-04 2023-09-07 Abitec Corporation Tablet dosage forms for lipid-based drug delivery systems
WO2025219169A1 (en) 2024-04-16 2025-10-23 Bayer Consumer Care Ag Stable soft capsule preparations with liquid fill for moisture sensitive active ingredients

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE0000773D0 (sv) * 2000-03-08 2000-03-08 Astrazeneca Ab New formulation
SE0102993D0 (sv) * 2001-09-07 2001-09-07 Astrazeneca Ab New self emulsifying drug delivery system
DE10353937A1 (de) * 2003-11-18 2005-06-30 Fresenius Medical Care Deutschland Gmbh Vorrichtung zur Übertragung einer Referenzflüssigkeit in ein Messgerät, Messgerät mit einer solchen Vorrichtung und Verfahren zur Übertragung einer Referenzflüssigkeit in ein Messgerät
GB0402679D0 (en) * 2004-02-06 2004-03-10 Novartis Ag Organic compounds
WO2005107773A2 (en) * 2004-05-06 2005-11-17 Emisphere Technologies, Inc. Solid dosage form of wetted heparin
NZ551196A (en) 2004-05-14 2010-08-27 Emisphere Tech Inc Compounds and compositions for delivering active agents
KR100654617B1 (ko) * 2004-09-23 2006-12-08 정해현 스틱이 내장된 커피믹스 팩과 커피믹스 박스
EP2488022B1 (en) 2009-10-16 2018-01-10 Mochida Pharmaceutical Co., Ltd. Compositions
US9968557B1 (en) 2011-02-09 2018-05-15 Florida A&M University Method of preparing modified multilayered microstructures with enhanced oral bioavailability
KR20240076240A (ko) * 2022-11-23 2024-05-30 (주) 바이오인프라생명과학 더블 에멀젼 구조의 초음파 감응형 약물전달체를 생성하는 방법

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995008983A1 (fr) * 1993-09-30 1995-04-06 Gattefosse S.A. Composition administrable par voie orale apte a former une microemulsion
WO1995009831A1 (en) * 1993-10-06 1995-04-13 Nicox S.A. Nitric esters having anti-inflammatory and/or analgesic activity and process for their preparation
WO1999056727A2 (en) * 1998-05-07 1999-11-11 Elan Corporation, Plc Solvent/cosolvent free microemulsion and emulsion preconcentrate drug delivery systems

Family Cites Families (79)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE7804231L (sv) * 1978-04-14 1979-10-15 Haessle Ab Magsyrasekretionsmedel
GB2105193B (en) 1981-09-04 1984-09-12 Glaxo Group Ltd Pharmaceutical compositions containing non-steroidal anti-inflammatory agents
JPS59227870A (ja) * 1983-06-07 1984-12-21 Yamanouchi Pharmaceut Co Ltd 新規２−グアニジノチアゾリン誘導体ならびにその製造法
US4554276A (en) 1983-10-03 1985-11-19 Pfizer Inc. 2-Amino-5-hydroxy-4-methylpyrimidine derivatives
US4522826A (en) 1984-02-08 1985-06-11 Richardson-Vicks Inc. Analgesic and anti-inflammatory compositions comprising diphenhydramine and methods of using same
US4552899A (en) * 1984-04-09 1985-11-12 Analgesic Associates Cough/cold mixtures comprising non-steroidal anti-inflammatory drugs
IL75400A (en) * 1984-06-16 1988-10-31 Byk Gulden Lomberg Chem Fab Dialkoxypyridine methyl(sulfinyl or sulfonyl)benzimidazoles,processes for the preparation thereof and pharmaceutical compositions containing the same
JPS6150978A (ja) 1984-08-16 1986-03-13 Takeda Chem Ind Ltd ピリジン誘導体およびその製造法
AU4640985A (en) 1984-08-31 1986-03-06 Nippon Chemiphar Co. Ltd. Benzimidazole derivatives
US4766117A (en) 1984-10-11 1988-08-23 Pfizer Inc. Antiinflammatory compositions and methods
US4704278A (en) 1984-10-17 1987-11-03 American Home Products Corp (Del) Fluidized magaldrate suspension
US4676984A (en) 1985-08-14 1987-06-30 American Home Products Corp. Rehydratable antacid composition
US4757060A (en) 1986-03-04 1988-07-12 Bristol-Myers Company Non-steroidal anti-inflammatory compositions protected against gastrointestinal injury with a combination of certain H1 and H2, receptor blockers
US4965065A (en) * 1986-04-29 1990-10-23 Bristol-Myers Squibb Company Gastroprotective process and compositions
US5043358A (en) * 1986-03-04 1991-08-27 Bristol-Myers Squibb Company Gastroprotective process
US5037815A (en) 1986-03-04 1991-08-06 Bristol-Myers Squibb Co. Non-steroidal anti-inflammatory compositions protected against gastrointestinal injury with a combination of certain H1 - and H2 -receptor blockers
GB2189698A (en) 1986-04-30 1987-11-04 Haessle Ab Coated omeprazole tablets
US5260333A (en) * 1986-08-08 1993-11-09 Bristol Myers Squibb Company Effect of a combination of a terbutaline, diphenhydramine and ranitidine composition on gastrointestinal injury produced by nonsteroidal anti-inflammatory compositions
GB8630273D0 (en) 1986-12-18 1987-01-28 Til Medical Ltd Pharmaceutical delivery systems
EP0320550A1 (en) 1987-12-18 1989-06-21 Bristol-Myers Company Non steroidal anti-inflammatory drug composition containing H1 blockers, H2 blockers, beta adrenergic agonists or combinations thereof and an alkalizing agent
SE8804629D0 (sv) 1988-12-22 1988-12-22 Ab Haessle New therapeutically active compounds
US5204118A (en) 1989-11-02 1993-04-20 Mcneil-Ppc, Inc. Pharmaceutical compositions and methods for treating the symptoms of overindulgence
NZ235877A (en) 1989-11-02 1992-09-25 Mcneil Ppc Inc Composition comprising acetaminophen or nsaid and an h 1 or h 2 receptor blocker and/or proton pump inhibitor for treating overindulgence
CA2104684A1 (en) * 1991-03-04 1992-09-05 Mahdi B. Fawzi Salts/ion pairs of non-steroidal anti-inflammatory drugs in various dosage forms
DE4131678A1 (de) 1991-04-13 1992-10-15 Beiersdorf Ag Stabile multiple emulsionen
DE69228738D1 (de) 1991-12-06 1999-04-29 Glaxo Group Ltd Zusammensetzungen zur Behandlung von entzündlichen Zuständen oder Analgesie, die Ranitidin Wismuth Citrat und einen NSAID enthalten
WO1993012817A1 (en) 1991-12-20 1993-07-08 Warner-Lambert Company Therapeutic combinations useful in the treatment of gastroesophageal reflux disease
US5294433A (en) * 1992-04-15 1994-03-15 The Procter & Gamble Company Use of H-2 antagonists for treatment of gingivitis
IT1256345B (it) 1992-08-20 1995-12-01 Esteri nitrici di derivati dell'acido 2-(2,6-di-alo-fenilammino) fenilacetico e procedimento per la loro preparazione
CA2144155A1 (en) 1992-09-29 1994-04-14 Robert T. Sims Ibuprofen-h2 antagonist combinations
IT1256450B (it) 1992-11-26 1995-12-05 Soldato Piero Del Esteri nitrici con attivita' farmacologica e procedimento per la loro preparazione
US5686105A (en) * 1993-10-19 1997-11-11 The Procter & Gamble Company Pharmaceutical dosage form with multiple enteric polymer coatings for colonic delivery
CH686761A5 (de) * 1993-05-27 1996-06-28 Sandoz Ag Galenische Formulierungen.
SE9301830D0 (sv) 1993-05-28 1993-05-28 Ab Astra New compounds
DK66493D0 (da) 1993-06-08 1993-06-08 Ferring A S Praeparater, isaer til brug ved behandling af inflammatoriske tarmsygdomme eller til at opnaa forbedret saarheling
SE9302396D0 (sv) 1993-07-09 1993-07-09 Ab Astra A novel compound form
US6054136A (en) 1993-09-30 2000-04-25 Gattefosse S.A. Orally administrable composition capable of providing enhanced bioavailability when ingested
US6312704B1 (en) * 1993-09-30 2001-11-06 Gattefosse, S.A. Orally administrable composition capable of providing enhanced bioavailability when ingested
US5514663A (en) 1993-10-19 1996-05-07 The Procter & Gamble Company Senna dosage form
EP0724441A1 (en) 1993-10-19 1996-08-07 The Procter & Gamble Company Picosulphate dosage form
US6025395A (en) * 1994-04-15 2000-02-15 Duke University Method of preventing or delaying the onset and progression of Alzheimer's disease and related disorders
US5643960A (en) * 1994-04-15 1997-07-01 Duke University Method of delaying onset of alzheimer's disease symptoms
SI0759899T1 (en) 1994-05-10 1999-12-31 Nicox S.A. Nitro compounds and their compositions having anti-inflammatory, analgesic and anti-thrombotic acitivities
EE03305B1 (et) 1994-07-08 2000-12-15 Astra Aktiebolag Paljuosaline tableteeritud annusvorm I
SE9500478D0 (sv) 1995-02-09 1995-02-09 Astra Ab New pharmaceutical formulation and process
JPH11504028A (ja) * 1995-04-24 1999-04-06 イースム リサーチ ディベロップメント カンパニー オブ ザ ヒーブル ユニバーシティ オブ エルサレム 油／水エマルジョンを作り出す自己乳化性配合物
US5955451A (en) * 1995-05-12 1999-09-21 The University Of Texas System Board Of Regents Methods of enhancing the therapeutic activity of NSAIDS and compositions of zwitterionic phospholipids useful therein
EP0760237A1 (en) * 1995-08-30 1997-03-05 Cipla Limited Oil-in-water microemulsions
SE9600070D0 (sv) 1996-01-08 1996-01-08 Astra Ab New oral pharmaceutical dosage forms
US6231888B1 (en) 1996-01-18 2001-05-15 Perio Products Ltd. Local delivery of non steroidal anti inflammatory drugs (NSAIDS) to the colon as a treatment for colonic polyps
WO1998022117A1 (en) 1996-11-22 1998-05-28 The Procter & Gamble Company Compositions for the treatment of gastrointestinal disorders containing bismuth, and nsaid and one or more antimicrobials
US6160020A (en) * 1996-12-20 2000-12-12 Mcneill-Ppc, Inc. Alkali metal and alkaline-earth metal salts of acetaminophen
SE510666C2 (sv) 1996-12-20 1999-06-14 Astra Ab Nya Kristallmodifikationer
SE510643C2 (sv) 1997-06-27 1999-06-14 Astra Ab Termodynamiskt stabil omeprazol natrium form B
SI0989851T1 (en) * 1997-07-29 2003-04-30 Pharmacia & Upjohn Company Self-emulsifying formulation for acidic lipophilic compounds
CA2301883A1 (en) 1997-09-11 1999-03-18 Nycomed Danmark A/S Modified release multiple-units compositions of non-steroid anti-inflammatory drug substances (nsaids)
US6326028B1 (en) * 1997-10-31 2001-12-04 Monsanto Company Alginate and gellan gum as tablet coating
WO1999038513A1 (en) 1998-01-30 1999-08-05 Sepracor Inc. R-lansoprazole compositions and methods
AU2481899A (en) 1998-01-30 1999-08-16 Sepracor, Inc. S-lansoprazole compositions and methods
EP0984012A3 (en) * 1998-08-31 2001-01-10 Pfizer Products Inc. Nitric oxide releasing oxindole prodrugs with analgesic and anti-inflammatory properties
JP5068401B2 (ja) 1998-09-28 2012-11-07 カプスゲル・ベルギウム・ナムローゼ・フェンノートシャップ Ｈｐｍｃカプセルを使用する腸及び結腸への送達
US6485747B1 (en) * 1998-10-30 2002-11-26 Monsanto Company Coated active tablet(s)
CN1236813C (zh) * 1998-12-11 2006-01-18 药品处理公司 水难溶性药物的自乳化组合物
US6635281B2 (en) * 1998-12-23 2003-10-21 Alza Corporation Gastric retaining oral liquid dosage form
US6267985B1 (en) 1999-06-30 2001-07-31 Lipocine Inc. Clear oil-containing pharmaceutical compositions
DE60017720T2 (de) 1999-03-31 2006-01-12 Pharmacia & Upjohn Co., Kalamazoo Pharmazeutische emulsionen für retroviral-protease hemmende verbindungen
IL145220A0 (en) 1999-05-20 2002-06-30 Par Pharmaceutical Inc Stabilized composition based on pyridinyl-sulfinyl-benzimidazoles and process
TWI243672B (en) * 1999-06-01 2005-11-21 Astrazeneca Ab New use of compounds as antibacterial agents
US6126816A (en) * 1999-07-14 2000-10-03 Ruiz, Jr.; Reuben F. Wastewater treatment device
US20020102301A1 (en) * 2000-01-13 2002-08-01 Joseph Schwarz Pharmaceutical solid self-emulsifying composition for sustained delivery of biologically active compounds and the process for preparation thereof
US6787164B2 (en) 2000-02-23 2004-09-07 Bioselect Innovations, Inc. Composition and method for treating the effects of diseases and maladies
SE0000773D0 (sv) * 2000-03-08 2000-03-08 Astrazeneca Ab New formulation
US20020044962A1 (en) 2000-06-06 2002-04-18 Cherukuri S. Rao Encapsulation products for controlled or extended release
SE0002476D0 (sv) 2000-06-30 2000-06-30 Astrazeneca Ab New compounds
US6544556B1 (en) 2000-09-11 2003-04-08 Andrx Corporation Pharmaceutical formulations containing a non-steroidal antiinflammatory drug and a proton pump inhibitor
US20020045184A1 (en) 2000-10-02 2002-04-18 Chih-Ming Chen Packaging system
FR2818905A1 (fr) * 2000-12-28 2002-07-05 Cll Pharma Compositions pharmaceutiques colloidales micellaires renfermant un principe actif lipophile
AR036354A1 (es) 2001-08-31 2004-09-01 Takeda Chemical Industries Ltd Preparacion solida
US7467633B2 (en) * 2005-03-10 2008-12-23 Huntsman Petrochemical Corporation Enhanced solubilization using extended chain surfactants

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995008983A1 (fr) * 1993-09-30 1995-04-06 Gattefosse S.A. Composition administrable par voie orale apte a former une microemulsion
WO1995009831A1 (en) * 1993-10-06 1995-04-13 Nicox S.A. Nitric esters having anti-inflammatory and/or analgesic activity and process for their preparation
WO1999056727A2 (en) * 1998-05-07 1999-11-11 Elan Corporation, Plc Solvent/cosolvent free microemulsion and emulsion preconcentrate drug delivery systems

Cited By (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7488497B2 (en) 1996-01-08 2009-02-10 Astrazeneca Ab Oral pharmaceutical dosage forms comprising a proton pump inhibitor and a NSAID
US6613354B2 (en) 1996-01-08 2003-09-02 Astrazeneca Ab Oral pharmaceutical dosage forms comprising a proton pump inhibitor and a NSAID
US8114435B2 (en) 1996-01-08 2012-02-14 Astrazeneca Ab Oral pharmaceutical dosage forms comprising a proton pump inhibitor and a NSAID
US7465803B2 (en) 2000-10-12 2008-12-16 Nicox S.A. Nitroderivatives as drugs for diseases having an inflammatory basis
US7629368B2 (en) 2000-10-12 2009-12-08 Nicox S.A. Nitroderivatives as drugs for diseases having an inflammatory basis
WO2004000273A1 (en) * 2002-06-25 2003-12-31 Nicox S.A. Oral pharmaceutical forms of liquid drugs having improved bioavailability
CN1319518C (zh) * 2002-06-25 2007-06-06 尼科克斯公司 具有改进的生物利用率的液体药物口服药物剂型
RU2323003C2 (ru) * 2002-06-25 2008-04-27 Никокс С.А. Пероральные фармацевтические формы жидких лекарственных средств, имеющих улучшенную биодоступность
EA017434B1 (ru) * 2003-02-27 2012-12-28 НОУВАСЕЛ ОСТРЕЙЛЮЭ ПиТиУай эЛТиДи Стабильная местная и/или мукозальная эмульсионная композиция (варианты), способ ее приготовления (варианты) и ее применение (варианты)
WO2004076561A1 (en) * 2003-02-27 2004-09-10 Novasel Australia Pty Ltd Poloxamer emulsion preparations
EP1597318A4 (en) * 2003-02-27 2006-06-14 Novasel Australia Pty Ltd POLOXAMEREMULSIONSZUBEREITUNGEN
US8802116B2 (en) 2003-02-27 2014-08-12 Novasel Australia Pty. Ltd. Poloxamer emulsion preparations
RU2406482C2 (ru) * 2005-07-26 2010-12-20 Никокс С.А. Фармацевтический состав нитрооксипроизводных нестероидных противовоспалительных средств
US8691869B2 (en) 2005-07-26 2014-04-08 Nicox S.A. Pharmaceutical formulation of nitrooxyderivatives of NSAIDs
WO2007012539A3 (en) * 2005-07-26 2007-04-19 Nicox Sa Pharmaceutical formulation of nitrooxyderivatives of nsaids
US9788564B2 (en) 2008-03-20 2017-10-17 Virun, Inc. Compositions containing non-polar compounds
US10220007B2 (en) 2008-03-20 2019-03-05 Virun, Inc. Compositions containing non-polar compounds
US10668029B2 (en) 2008-03-20 2020-06-02 Virun, Inc. Compositions containing non-polar compounds
US10335385B2 (en) 2010-06-21 2019-07-02 Virun, Inc. Composition containing non-polar compounds
US20230277464A1 (en) * 2022-03-04 2023-09-07 Abitec Corporation Tablet dosage forms for lipid-based drug delivery systems
WO2025219169A1 (en) 2024-04-16 2025-10-23 Bayer Consumer Care Ag Stable soft capsule preparations with liquid fill for moisture sensitive active ingredients

Also Published As

Publication number Publication date
JP2003525893A (ja) 2003-09-02
CZ303524B6 (cs) 2012-11-14
MXPA02008658A (es) 2003-02-24
DE60115402T2 (de) 2006-08-03
EP1267831B1 (en) 2005-11-30
BR0109012B1 (pt) 2014-08-26
EE200200483A (et) 2004-02-16
AU3787501A (en) 2001-09-17
NO20024194D0 (no) 2002-09-03
SI1267831T1 (sl) 2006-04-30
AR027554A1 (es) 2003-04-02
IL151380A0 (en) 2003-04-10
CA2401857A1 (en) 2001-09-13
US20100266683A1 (en) 2010-10-21
CN1283229C (zh) 2006-11-08
NO331921B1 (no) 2012-04-30
IS6538A (is) 2002-09-03
HK1053795A1 (en) 2003-11-07
AU2001237875B2 (en) 2005-05-12
KR100771318B1 (ko) 2007-10-29
SE0000774D0 (sv) 2000-03-08
ZA200207109B (en) 2003-12-04
SK285749B6 (sk) 2007-07-06
KR20030011788A (ko) 2003-02-11
ATE311173T1 (de) 2005-12-15
HUP0300539A3 (en) 2003-09-29
JP4656479B2 (ja) 2011-03-23
DE60115402D1 (de) 2006-01-05
RU2002122745A (ru) 2004-03-20
MY137749A (en) 2009-03-31
PL358617A1 (en) 2004-08-09
US20030077303A1 (en) 2003-04-24
EP1267831A1 (en) 2003-01-02
HU229103B1 (en) 2013-07-29
CN1416336A (zh) 2003-05-07
SK12582002A3 (sk) 2003-04-01
ES2253354T3 (es) 2006-06-01
CZ20023006A3 (cs) 2003-02-12
HUP0300539A2 (hu) 2003-07-28
BR0109012A (pt) 2003-06-03
NO20024194L (no) 2002-09-03
DK1267831T3 (da) 2006-03-20
RU2275908C2 (ru) 2006-05-10
US7736666B2 (en) 2010-06-15
UA76098C2 (en) 2006-07-17

Similar Documents

Publication Publication Date Title
US20100266683A1 (en) New self emulsifying drug delivery system
CA2401498C (en) New self emulsifying drug delivery system
AU2001237875A1 (en) New self emulsifying drug delivery system
AU2001237876A1 (en) New self emulsifying drug delivery system
EP1427392B1 (en) New self emulsifying drug delivery system
HK1050632B (en) Self emulsifying drug delivery system, wherein the fatty agent is optional
PL203549B1 (pl) Kompozycja farmaceutyczna w postaci prekoncentratu emulsji, jednostkowa posta c dawkowana i zastosowanie kompozycji farmaceutycznej

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: IN/PCT/2002/01101/MU

Country of ref document: IN

WWE Wipo information: entry into national phase

Ref document number: 151380

Country of ref document: IL

WWE Wipo information: entry into national phase

Ref document number: 521008

Country of ref document: NZ

WWE Wipo information: entry into national phase

Ref document number: 2401857

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 12582002

Country of ref document: SK

WWE Wipo information: entry into national phase

Ref document number: 2002/07109

Country of ref document: ZA

Ref document number: PA/a/2002/008658

Country of ref document: MX

Ref document number: 200207109

Country of ref document: ZA

Ref document number: 2001237875

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 10221079

Country of ref document: US

Ref document number: 02079427

Country of ref document: CO

Ref document number: PV2002-3006

Country of ref document: CZ

ENP Entry into the national phase

Ref document number: 2001 564740

Country of ref document: JP

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 1020027011733

Country of ref document: KR

WWE Wipo information: entry into national phase

Ref document number: 018062938

Country of ref document: CN

WWE Wipo information: entry into national phase

Ref document number: 2001910304

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 2002 2002122745

Country of ref document: RU

Kind code of ref document: A

WWP Wipo information: published in national office

Ref document number: 2001910304

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 1020027011733

Country of ref document: KR

WWP Wipo information: published in national office

Ref document number: PV2002-3006

Country of ref document: CZ

WWG Wipo information: grant in national office

Ref document number: 2001237875

Country of ref document: AU

WWG Wipo information: grant in national office

Ref document number: 2001910304

Country of ref document: EP